Otago Study Links pTau181 to Memory Concerns in 45-Year-Olds as Early Alzheimer’s Clue
Updated
Updated · ScienceAlert · May 21
Otago Study Links pTau181 to Memory Concerns in 45-Year-Olds as Early Alzheimer’s Clue
3 articles · Updated · ScienceAlert · May 21
University of Otago researchers found the blood protein pTau181 was associated with self-reported memory and thinking concerns in 45-year-olds in the long-running Dunedin Study.
The finding suggests Alzheimer’s-related changes may begin decades before typical diagnosis in people’s 70s or later, making midlife a key window to spot risk earlier.
Researchers did not find a link between pTau181 and MRI brain measures or cognitive test performance at age 45, leaving open whether the marker reflects the earliest disease stage or is more useful later in life.
Blood biomarkers could offer a less invasive alternative to tests such as lumbar punctures and, combined with subjective memory complaints, may help distinguish early pathology from normal aging.
The team plans to keep tracking the cohort as it ages, with the broader aim of enabling earlier prevention through lifestyle changes and treatment before cognitive loss advances.
Could early blood tests like pTau217 revolutionize Alzheimer's prevention by detecting risk decades before symptoms—what barriers remain before this becomes routine?
With women facing higher Alzheimer's risk, how might menopause-specific screening and prevention strategies change midlife health care in the next decade?
pTau181 as an Early Alzheimer’s Biomarker: Insights from the Otago Study and the Evolving Role of Blood Tests in Diagnosis and Prevention
Overview
The Otago Study, part of the Dunedin Multidisciplinary Health and Development Study, followed over 1,000 New Zealanders from birth and collected detailed health data at age 45, including blood tests for plasma pTau181, brain scans, and cognitive assessments. Researchers found a wide range of pTau181 levels—a known Alzheimer’s disease biomarker—among participants. However, higher pTau181 did not link to cognitive decline or brain changes at this age. This suggests that while early Alzheimer’s markers can be detected in midlife, their effects on thinking and brain structure may not appear until later, highlighting the importance of ongoing monitoring and research.